TIXiMED Announces a $2.65M Program-Related Investment from the Helmsley Charitable Trust to Initiate Clinical Trials of Its Novel Oral Therapy for Beta Cell Survival and Function
December 19, 2024 10:47 AM Eastern Standard Time BIRMINGHAM, Ala.–(BUSINESS WIRE)–TIXiMED, Inc. (https://tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, has…